Group 1 - The core viewpoint of the news is that the approval timeline for clinical trial applications of innovative drugs is expected to accelerate, benefiting the innovative drug industry and attracting significant market interest [1] - The Hang Seng Innovative Drug ETF (520500) has seen continuous net inflows for five consecutive trading days since June 10, 2025, reaching new highs in both shares and scale since its inception [1] - The scale of the Hang Seng Innovative Drug ETF (520500) has increased by 338% since its listing on December 27, 2024, with the latest figures showing 401 million shares and a scale of 653 million yuan as of June 25, 2025 [1] Group 2 - The Hang Seng Innovative Drug ETF (520500) is the only ETF in the A-share market tracking the Hang Seng Innovative Drug Index, selecting nearly 40 leading biopharmaceutical companies with strong R&D capabilities and high growth potential [2] - The ETF supports T+0 trading, providing high liquidity and trading efficiency advantages [2] - With improving policy expectations and the acceleration of domestic innovative drug companies going global, Chinese pharmaceutical companies are expected to reshape the global innovative drug landscape [2]
创新药临床试验审评审批提速！恒生创新药ETF（520500）最新份额、规模齐创新高
Sou Hu Cai Jing·2025-06-17 03:27